Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.
about
Clinical studies in lysosomal storage diseases: Past, present, and futureAgalsidase alfa: a review of its use in the management of Fabry diseaseReceptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry diseaseMultifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A geneGenetic susceptibility to ischemic stroke.Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) dataAnalysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry.Fabry's disease discovered with chance urinary mulberry cells: a case report.Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS).Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's diseaseTherapeutic approaches for lysosomal storage diseasesHypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.Genetic stroke syndromesFabryScan: a screening tool for early detection of Fabry disease.New information on the genetics of stroke.Dysregulated autophagy contributes to podocyte damage in Fabry's disease.Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complicationsUpdate on role of agalsidase alfa in management of Fabry disease.Candidate molecules for chemical chaperone therapy of GM1-gangliosidosis.Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneysPharmacological chaperone therapy for Fabry diseaseRenal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.Quality of life in patients with Fabry disease: a systematic review of the literature.Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease.Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutationEnzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experienceLong-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysisEffects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry diseasePatients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.
P2860
Q27025186-B556CD02-E0B0-4FD3-97FD-F28439508CA8Q28274194-24D6C081-BE91-464D-8ADD-6B838EB07555Q28477142-F7C6BDEE-A6E1-446B-AD79-39F7618562A4Q28485955-1D57932F-863F-4F2C-B9DD-59D8A4D845C6Q30414709-4FD552D8-C430-483C-84B8-C1B42625494FQ30578294-4FD1CF10-3677-43A1-84C8-0B96177C05B8Q30632134-5938D644-B9BD-4FFC-861F-701C508763F5Q33628288-7B8E3C84-4436-4B7C-B9FF-9A8854F80589Q33645550-DF075E02-9A37-48BF-B8D1-7F51FC3EC08FQ33776219-6763B0A8-D12B-4A64-B351-E38972F25D32Q33886219-15A78105-83A3-4B3A-B34C-C5DCB9103652Q33934452-E27024F5-A081-4DB5-9A67-8BCCAFC6487CQ33937755-53C188ED-93F1-4A6D-83AF-607419582B8BQ34311420-F2686968-0F75-4752-94F4-6066FC2AA3A0Q34460145-0209AB4D-CB7F-4869-823E-71A0A9A7E392Q34522989-9345C4A8-A3E8-4E97-B67F-2234F527B010Q34641339-D2F31252-B164-43ED-B575-77CF8CF42FD4Q34664010-8EF3FB63-A671-46C6-905D-7810AFB19321Q34730562-809DFA1B-64B3-4F51-A656-6EFBC645DA6CQ34805283-2B9B888B-AC64-41AA-B07C-33905C6737CDQ34883178-77EA8A3B-C5A4-47F6-8E90-3912F85B6AFBQ34985010-DF21DF1C-9C2D-489D-99CC-4184C8E540E9Q35009083-2EFDF267-E154-4092-BC88-DDF2143679C9Q35550696-385B4F74-7CCE-4DCA-9EEF-DBBAFCE264D0Q35692435-B22DCFE5-8622-487B-B4EA-9C4F1A088D3EQ35719001-A5D828AE-17A7-484A-9366-934950086C44Q35755438-D21EDA78-1D80-4CA1-8BBE-CBF3163F071AQ35788989-9B577C7D-7027-465C-8F06-4224A00A2738Q35795427-D1CCE9E6-8ABF-4976-9079-F76063D80EE2Q35848678-BC35F43E-897F-47D6-AC1C-2ED1D836B8E7Q35849151-8E84F763-4CF7-431A-9E85-33C7E67B7134Q36061578-8304D1A4-AE13-4F5F-8243-0DFFD669DE2BQ36105190-6449C540-A389-4B5F-8BE9-C07E9A383830Q36272033-0073E64F-8B82-4342-901D-3418F39402A7Q36309032-AF4B651A-91FB-42E7-B1BC-92A907E22335Q36433306-BE960D33-6DC6-4BE0-8DFC-3D13376B2ED5Q36571559-0AB6971E-3BE5-4DC2-9CA9-2F8FA7172227Q36590934-A69F2CF7-F391-4CB7-B95B-A3F94B4E2F56Q36624746-C1CF0873-4A41-422F-A76E-3ADA7BF7591DQ36767452-65C93190-99B2-432F-9403-B79A149C4C75
P2860
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Enzyme replacement therapy wit ...... an analysis of registry data.
@ast
Enzyme replacement therapy wit ...... an analysis of registry data.
@en
Enzyme replacement therapy wit ...... an analysis of registry data.
@nl
type
label
Enzyme replacement therapy wit ...... an analysis of registry data.
@ast
Enzyme replacement therapy wit ...... an analysis of registry data.
@en
Enzyme replacement therapy wit ...... an analysis of registry data.
@nl
prefLabel
Enzyme replacement therapy wit ...... an analysis of registry data.
@ast
Enzyme replacement therapy wit ...... an analysis of registry data.
@en
Enzyme replacement therapy wit ...... an analysis of registry data.
@nl
P2093
P1433
P1476
Enzyme replacement therapy wit ...... an analysis of registry data.
@en
P2093
Fabry Outcome Survey investigators
G Sunder-Plassmann
J T R Clarke
R Giugliani
R Schiffmann
P304
P356
10.1016/S0140-6736(09)61493-8
P407
P50
P577
2009-12-01T00:00:00Z